Where does Orlucent Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Orlucent Inc. ranks #49,382 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Orlucent Inc. hold?

Orlucent Inc. holds 5 US utility patents granted between 2019 and 2024, spanning 7 technology areas.

What is Orlucent Inc.'s Innovation Score?

Orlucent Inc. has an Innovation Score of 29.0 out of 100 (29th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Orlucent Inc. focus on?

Orlucent Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 4 patents, ranking #3,645 of 7,127 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Orlucent Inc.'s patent grant rate increasing or decreasing?

Orlucent Inc.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Orlucent Inc.'s patents?

Orlucent Inc.'s patents average 15.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Orlucent Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Orlucent Inc.

USPTO PatentsView assignee record - 5 granted patents across 7 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Orlucent ranks #49,382 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 7 technology areas.

#49,382
of 49,997 US assignees by volume: 29th percentile
by Innovation Score (29.0/100): 15.0
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R49382 · US Corporation #49,382 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #49,382/49,997
PHOTO-FINISH Oribase Pharma
CPC-NARROW A61B · 7 areas
INNOV-THIN 29.0/100
CLAIMS-RICH 15.0 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Oribase Pharma (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Orlucent’s 29.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (21%) Velocity 4.4 pts (15%) Breadth 9.4 pts (32%) Claim depth 9.0 pts (31%)

Qualcomm Incorporated · highest

85
Beijing Bio-targetin… · near

29
Nevis Industries · near

29
Nvidia Technology UK · near

29
Orlucent · this assignee

29
Unitract Syringe PTY · near

29
3D Lighting… · lowest

7

What this shows Orlucent's Innovation Score is 29.0/100 (29th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Orlucent?

Each dot is one of Orlucent’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Orlucent’s own 15.0 claims/patent is ABOVE the 9.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Orlucent vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Orlucent's grants concentrate

Orlucent Inc. is a focused PatentsView assignee: 7 CPC subclasses with 80% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, Orlucent sits between Oribase Pharma and Osang Healthcare Co., Ltd..

Orlucent's three-year grant acceleration

Orlucent Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Oribase Pharma

5
Orient Service

5
Orion Biotech

5
Orion Innovations

5
Orthogen

5
Ortlieb Sportarik…

5
Oryza OIL & FAT C…

5
Osang Healthcare

5
Orlucent ◀

5

What this shows Orlucent holds 5 patents at rank #49,309, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Orlucent

By rank, the assignees closest to #49,309 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Orlucent's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Orlucent, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Orlucent ranks #3,645 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (29 here).

Beijing Bio-targeting Therapeutics Technology Inc. 29 Nvidia Technology UK Limited 29 Unitract Syringe PTY Ltd 29 Nevis Industries LLC 29

Orlucent's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 29th percentile higher than 29% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Orlucent Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	20.0%
2020	1	20.0%
2021	1	20.0%
2023	1	20.0%
2024	1	20.0%

Which technologies does Orlucent Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 4

Y10T - Technical Subjects Covered BY Former US Classification 3

H04N - Pictorial Communication, e.g. Television 3

G06T - Image Data Processing OR Generation, IN General 3

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Orlucent Inc.'s patent record in context - here's where to go next.

Orlucent Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 80% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #49,382 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Orlucent Inc. against Oribase Pharma, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.